

GROENHUYSEN WILHELMUS CM

Form 4

March 06, 2019

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
GROENHUYSEN WILHELMUS CM

(Last) (First) (Middle)

C/O NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300

(Street)

MALVERN, PA 19355

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
NovoCure Ltd [NVCR]

3. Date of Earliest Transaction (Month/Day/Year)  
03/04/2019

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_ Director \_\_\_ 10% Owner  
 Officer (give title below) \_\_\_ Other (specify below)  
Chief Financial Officer

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
\_\_\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				Code	V Amount or Price			
Ordinary Shares	03/04/2019		M		(1) 18,766 A \$ 3.44	85,030	D	
Ordinary Shares	03/04/2019		S		(2) 5,396 D \$ 53.906	79,634	D	
Ordinary Shares	03/04/2019		S		(3) 3,400 D \$ 54.558	76,234	D	
Ordinary Shares	03/04/2019		S		4,748 D \$ 56.035	71,486	D	

Edgar Filing: GROENHUYSEN WILHELMUS CM - Form 4

					(4)		
Ordinary Shares	03/04/2019	S	5,222	D	\$ 56.521	66,264	D
					(5)		
Ordinary Shares	03/04/2019	M	40,000	A	\$ 3.44	106,264	D
			(1)				
Ordinary Shares	03/04/2019	S	25,851	D	\$ 52.903	80,413	D
					(6)		
Ordinary Shares	03/04/2019	S	4,207	D	\$ 53.816	76,206	D
					(7)		
Ordinary Shares	03/04/2019	S	2,800	D	\$ 54.543	73,406	D
					(8)		
Ordinary Shares	03/04/2019	S	2,800	D	\$ 55.948	70,606	D
					(9)		
Ordinary Shares	03/04/2019	S	4,342	D	\$ 56.503	66,264	D
					(10)		
Ordinary Shares	03/05/2019	M	31,234	A	\$ 3.44	97,498	D
			(1)				
Ordinary Shares	03/05/2019	S	31,234	D	\$ 53.404	66,264	D
					(11)		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. D	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number

Options to Buy Ordinary Shares	\$ 3.44	03/04/2019	M	18,766	<u>(12)</u>	12/13/2021	Ordinary Shares	18,766
Options to Buy Ordinary Shares	\$ 3.44	03/04/2019	M	40,000	<u>(12)</u>	12/13/2021	Ordinary Shares	40,000
Options to Buy Ordinary Shares	\$ 3.44	03/05/2019	M	31,234	<u>(12)</u>	12/13/2021	Ordinary Shares	31,234

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
GROENHUYSEN WILHELMUS CM C/O NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN, PA 19355			Chief Financial Officer	

## Signatures

/s/ Kimberly Burke, Attorney in fact for Wilhelmus CM  
Groenhuisen

03/06/2019

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuisen.  
On March 4, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuisen, Mr. Groenhuisen sold 5,396 shares in multiple trades at prices ranging from \$53.35 to \$54.34. The price reported above reflects the weighted average sale price. Mr. Groenhuisen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- (2) On March 4, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuisen, Mr. Groenhuisen sold 3,400 shares in multiple trades at prices ranging from \$54.35 to \$55.34. The price reported above reflects the weighted average sale price. Mr. Groenhuisen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- (3) On March 4, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuisen, Mr. Groenhuisen sold 4,748 shares in multiple trades at prices ranging from \$55.35 to \$56.34. The price reported above reflects the weighted average sale price. Mr. Groenhuisen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- (4) On March 4, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuisen, Mr. Groenhuisen sold 5,222 shares in multiple trades at prices ranging from \$56.35 to \$56.63. The price reported above reflects the weighted average sale price. Mr. Groenhuisen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- (5) On March 4, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuisen, Mr. Groenhuisen sold 5,222 shares in multiple trades at prices ranging from \$56.35 to \$56.63. The price reported above reflects the weighted average sale price. Mr. Groenhuisen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

## Edgar Filing: GROENHUYSEN WILHELMUS CM - Form 4

- (6) On March 4, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuisen, Mr. Groenhuisen sold 25,851 shares in multiple trades at prices ranging from \$52.34 to \$53.32. The price reported above reflects the weighted average sale price. Mr. Groenhuisen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- (7) On March 4, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuisen, Mr. Groenhuisen sold 4,207 shares in multiple trades at prices ranging from \$53.35 to \$54.34. The price reported above reflects the weighted average sale price. Mr. Groenhuisen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- (8) On March 4, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuisen, Mr. Groenhuisen sold 2,800 shares in multiple trades at prices ranging from \$54.35 to \$55.34. The price reported above reflects the weighted average sale price. Mr. Groenhuisen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- (9) On March 4, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuisen, Mr. Groenhuisen sold 2,800 shares in multiple trades at prices ranging from \$55.35 to \$56.34. The price reported above reflects the weighted average sale price. Mr. Groenhuisen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- (10) On March 4, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuisen, Mr. Groenhuisen sold 4,342 shares in multiple trades at prices ranging from \$56.39 to \$56.61. The price reported above reflects the weighted average sale price. Mr. Groenhuisen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- (11) On March 5, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuisen, Mr. Groenhuisen sold 31,234 shares in multiple trades at prices ranging from \$53.35 to \$53.56. The price reported above reflects the weighted average sale price. Mr. Groenhuisen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- (12) Fully vested as of the date hereof.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.